12 results about "Hepatic encephalopathy" patented technology

The present invention relates to the use of selective aquaporin inhibitors, e.g., of aquaporin-4 or aquaporin-2, e.g., certain phenylbenzamide compounds, for the prophylaxis, treatment and control of aquaporin-mediated conditions, e.g., diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord, e.g., following trauma or ischemic stroke, as well as the edema associated with glioma, meningitis, acute mountain sickness, epileptic seizures, infections, metabolic disorders, hypoxia, water intoxication, hepatic failure, hepatic encephalopathy, diabetic ketoacidosis, abscess, eclampsia, Creutzfeldt-Jakob disease, and lupus cerebritis, as well as edema consequent to microgravity and / or radiation exposure, as well as edema consequent to invasive central nervous system procedures, e.g., neurosurgery, endovascular clot removal, spinal tap, aneurysm repair, or deep brain stimulation, as well as retinal edema), as well as hyponatremia and excess fluid retention, and diseases such as epilepsy, retinal ischemia and other diseases of the eye associated with abnormalities in intraocular pressure and / or tissue hydration, myocardial ischemia, myocardial ischemia / reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, and neuromyelitis optica, as well as migraines, as well as to novel assays for identifying aquaporin inhibitors.

The invention relates to the field of biomedical application of inorganic materials, in particular to application of lanthanum carbonate in preparation of a medicine for treating hepatic encephalopathy. According to the application of lanthanum carbonate in preparation of the medicine for treating hepatic encephalopathy, the medicine comprises lanthanum carbonate and pharmaceutically acceptable auxiliary materials, the lanthanum carbonate comprises any one or more of lanthanum carbonate hydrate and basic lanthanum carbonate, the medicine is ground and then mixed with food to prepare a medicine mixture, and the medicine mixture is prepared into the medicine for treating hepatic encephalopathy. The mass ratio of the lanthanum carbonate in the medicine mixture is 1-10%. According to the application, the blood ammonia is reduced based on the glutaminase, the hepatic encephalopathy is reversed by reducing the blood ammonia and systemic inflammation, and the liver function is recovered by regulating the inflammation, so that the hepatic encephalopathy is favorably cured, a good treatment effect is shown, and a new candidate medicine is provided for clinically treating the hepatic encephalopathy.

The application discloses a kind of based on brain structure image's hepatic encephalopathy evaluation method and system, the method includes: obtaining the brain structure image data of subject brain;Based on brain structure image data, the feature parameter of characterizing brain tissue morphology is extracted;The characteristic parameter is handled by pre-training disease progression evaluation model, and the space-time progression trajectory of brain structure abnormality is inferred;Based on space-time progression trajectory, the disease subtype and disease progression stage to which the subject belongs are determined;Based on disease subtype and disease progression stage, evaluation information for characterizing the disease state of hepatic encephalopathy is generated.The space-time progression trajectory of brain structure abnormality is inferred based on cross-sectional image data, which overcomes the dependence on massive longitudinal tracking data, realizes the objective typing and staging of hepatic encephalopathy based on neurobiology, thereby effectively solving the technical problems of difficult to track disease evolution and individualized evaluation.

The application relates to the biomedical application field of inorganic materials, and particularly relates to application of lanthanum carbonate in preparation of a medicine for treating hepatic encephalopathy. The application relates to application of lanthanum carbonate in preparation of a medicine for treating hepatic encephalopathy, wherein the medicine comprises lanthanum carbonate and pharmaceutically acceptable adjuvants, and the lanthanum carbonate comprises any one or more of lanthanum carbonate hydrate and basic lanthanum carbonate. The application is based on the fact that glutamine enzyme can reduce blood ammonia, and the hepatic encephalopathy is reversed by reducing blood ammonia and systemic inflammation, the liver function is recovered by regulating inflammation, thereby helping to cure the hepatic encephalopathy, and good treatment effect is shown, so that a new candidate medicine for clinically treating the hepatic encephalopathy is provided.

The invention relates to application of sevelamer. The medicine is particularly applied to treatment of hepatic encephalopathy. According to the method for orally taking the sevelamer compound preparation, the level of ammonia in blood can be remarkably reduced to the normal level, bile acid in the intestinal tract is combined, system inflammation is reduced, and therefore the sevelamer compound preparation is beneficial to curing hepatic encephalopathy, and no obvious side effect is found; the sevelamer oral administration method provided by the invention has a remarkable treatment effect on hepatic encephalopathy, a new candidate treatment medicine is expected to be brought to clinical hepatic encephalopathy, and meanwhile, the range of indications of sevelamer in clinical treatment is widened.

5′-O-Phenylacetyluridine effectively delivers both phenylacetate and uridine to a subject. It can be used to treat hepatic encephalopathy and genetic disorders of the hepatic nitrogen cycle.

The application belongs to the technical field of biological medicine, and particularly relates to application of quinacrine, a pharmaceutically acceptable salt or a solvate thereof in preparation of a medicine for treating hepatic encephalopathy. The application finds that quinacrine can target and inhibit a PLA2G3 / cGAS-STING signal axis of microglia cells, and is used for treating hepatic encephalopathy. Specifically, quinacrine blocks a decrease of mitochondrial membrane phospholipid PE and activation of a cGAS-STING pathway induced by high ammonia by inhibiting PLA2G3 activity, thereby reducing release of proinflammatory factors (IL-1beta, IL-6, TNF-alpha, etc.), reversing abnormal activation of microglia cells to proinflammatory type, and inhibiting synaptic damage of neurons (restoring expression of PSD95 and SYN and morphology of dendritic spines), and finally improving cognitive function.

This utility model belongs to the field of experimental equipment technology, and discloses an ion monitoring device for a rabbit hepatic encephalopathy experimental model, including: an operating table with a monitoring system installed on it; the monitoring system includes a first base with a first fixing rod fixed in the center and two fixing clips on the first fixing rod; a tension transducer with its input end detachably connected to the fixing clips and a three-way valve detachably connected to the input end, with an endotracheal tube detachably connected to the three-way valve for monitoring respiratory rate; and a pressure transducer with its input end detachably connected to the fixing clip and a three-way valve detachably connected to the input end, with an arterial cannula detachably connected to the three-way valve for monitoring changes in arterial blood pressure, heart rate, and respiratory rate during the progression of rabbit hepatic encephalopathy (early, middle, progressive, and recovery phases), thereby increasing the scientific rigor and repeatability of the experimental operation.

Use of an aromatic L-amino acid decarboxylase as a marker in a detection product for hepatic encephalopathy. It has been confirmed that the abundance of aromatic L-amino acid decarboxylase genes encoded by gut microbiota, as well as the product of aromatic L-amino acid decarboxylase, phenylethylamine, are increased in patients with hepatic encephalopathy; and compared with blood ammonia, hepatic encephalopathy can be more accurately diagnosed by means of phenylethylamine. This suggests that the occurrence of hepatic encephalopathy and the degree of progression of the disease can be quickly confirmed by detecting the patients' feces and serum, which increases the demand for clinical detection of hepatic encephalopathy. It has been confirmed that the baseline serum phenylethylamine level can effectively predict the incidence of hepatic encephalopathy at 3 months after TIPS surgery, which provides a detection means for early warning of hepatic encephalopathy.

Methods for identifying biomarkers indicative of an increased risk for developing hepatic encephalopathy (HE) following transjugular intrahepatic portosystemic shunting (TIPS) are provided. Methods include determining whether the subject has a decreased level of metabolites following transjugular intrahepatic portosystemic shunting (TIPS), and / or determining a level of intrahepatic shunting in the subject. Methods for preventing and treating a subject having or at risk of having HE identified by the methods disclosed.

A system for screening hepatic encephalopathy (HE) based on critical flicker fusion frequency (CFFF) detection using visual perception thresholds. The system comprises a frequency setter module that generates a controlled sequence of flickering light signals, an internal oscillator for precise timing, and a frequency tracker module that adjusts the flicker rate based on patient feedback. A frequency re-setter module ensures visual memory effects are minimized by introducing a non-flickering baseline between steps. The system includes a light controller that emits spectrally filtered, intensity-calibrated light optimized for retinal sensitivity. A patient feedback input module records flicker perception responses, while a recording module logs test parameters and outcomes. A secure communication module transmits this data to a remote interface for clinical evaluation. The system dynamically adapts to patient input, enhancing accuracy in determining CFFF, a validated biomarker for minimal HE, thereby enabling early, objective, and non- invasive screening of cognitive dysfunction.

Provided is a Bifidobacterium lactis. The Bifidobacterium lactis is Bifidobacterium animalis subsp. lactis BL-11, and the preservation number of the Bifidobacterium animalis subsp. lactis BL-11 is CGMCC No. 20847. The provided Bifidobacterium animalis subsp. lactis can improve intestine metabolism disorder and normalize the composition of intestine microbiome so as to improve height, suppresses obesity, promote infant and youth physical development and mental development, and prevent and treat mental disorders, said mental disorders including anxiety, depression, attention-deficit / hyperactivity disorder, autism, schizophrenia, hepatic encephalopathy, anorexia, Tourette syndrome, and Asperger syndrome.